Sutro Biopharma(STRO) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights – On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and dual-payload ADCs – – Entered research collaboration with the FDA to advance regulatory standards for ADCs – – Industry veteran Greg Chow appointed as Chief Financial Officer – – Cash, cash equivalents and marketab ...